Neutralizing tumor-promoting chronic inflammation: A magic bullet?

Lisa Coussens, Laurence Zitvogel, A. Karolina Palucka

Research output: Contribution to journalArticle

515 Citations (Scopus)

Abstract

There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalScience
Volume339
Issue number6117
DOIs
StatePublished - Jan 18 2013

Fingerprint

Magic
Inflammation
Neoplasms
Blood Vessels
Radiotherapy

ASJC Scopus subject areas

  • General

Cite this

Neutralizing tumor-promoting chronic inflammation : A magic bullet? / Coussens, Lisa; Zitvogel, Laurence; Palucka, A. Karolina.

In: Science, Vol. 339, No. 6117, 18.01.2013, p. 286-291.

Research output: Contribution to journalArticle

Coussens, Lisa ; Zitvogel, Laurence ; Palucka, A. Karolina. / Neutralizing tumor-promoting chronic inflammation : A magic bullet?. In: Science. 2013 ; Vol. 339, No. 6117. pp. 286-291.
@article{c1319a38a1884f82a2fb57c7f1857587,
title = "Neutralizing tumor-promoting chronic inflammation: A magic bullet?",
abstract = "There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.",
author = "Lisa Coussens and Laurence Zitvogel and Palucka, {A. Karolina}",
year = "2013",
month = "1",
day = "18",
doi = "10.1126/science.1232227",
language = "English (US)",
volume = "339",
pages = "286--291",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6117",

}

TY - JOUR

T1 - Neutralizing tumor-promoting chronic inflammation

T2 - A magic bullet?

AU - Coussens, Lisa

AU - Zitvogel, Laurence

AU - Palucka, A. Karolina

PY - 2013/1/18

Y1 - 2013/1/18

N2 - There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.

AB - There have been substantial advances in cancer diagnostics and therapies in the past decade. Besides chemotherapeutic agents and radiation therapy, approaches now include targeting cancer cell-intrinsic mediators linked to genetic aberrations in cancer cells, in addition to cancer cell-extrinsic pathways, especially those regulating vascular programming of solid tumors. More recently, immunotherapeutics have entered the clinic largely on the basis of the recognition that several immune cell subsets, when chronically activated, foster tumor development. Here, we discuss clinical and experimental studies delineating protumorigenic roles for immune cell subsets that are players in cancer-associated inflammation. Some of these cells can be targeted to reprogram their function, leading to resolution, or at least neutralization, of cancer-promoting chronic inflammation, thereby facilitating cancer rejection.

UR - http://www.scopus.com/inward/record.url?scp=84872445265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872445265&partnerID=8YFLogxK

U2 - 10.1126/science.1232227

DO - 10.1126/science.1232227

M3 - Article

C2 - 23329041

AN - SCOPUS:84872445265

VL - 339

SP - 286

EP - 291

JO - Science

JF - Science

SN - 0036-8075

IS - 6117

ER -